Skip to content

Study · Case report or series · n = 1 · 2026

2 results

Semaglutide-associated Twiddler syndrome.

Seiler T, Noti F, Laimer M, Reichlin T, Haeberlin A

JCEM case reports6 May 2026

PMID42100587 (opens in a new tab)PMCIDPMC13148150 (opens in a new tab)DOI10.1210/jcemcr/luag103 (opens in a new tab)PepBankPUB-42100587
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with refractory obesity and an ICD, semaglutide was followed by rapid weight loss of 25 kg.

    In plain wordsIn one woman with obesity and a heart device, semaglutide was followed by rapid weight loss of 25 kg.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Weight loss
    25 kg
    case patient

    Source sentences

    Summary
    After rapid weight loss of 25 kg, she developed painful device mobility and right ventricular lead dysfunction.
    1 context sentence
    Summary · context
    52-year-old woman with cardiac sarcoidosis and a dual-chamber implantable cardioverter defibrillator (ICD) was treated with semaglutide for refractory obesity (body mass index (BMI) of 40.1 (kg/m2)).
  2. 02HumanCase report or seriesSafety outcome

    In a woman with cardiac sarcoidosis and an ICD, rapid weight loss on semaglutide was followed by device mobility, right ventricular lead dysfunction and lead entanglement consistent with Twiddler syndrome.

    In plain wordsIn one woman with a heart device, rapid weight loss on semaglutide was followed by device movement and lead problems (Twiddler syndrome).

    Peptide
    Semaglutide
    Outcome
    Not applicableTwiddler syndrome with ICD lead dysfunction
    Study

    n = 1

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After rapid weight loss of 25 kg, she developed painful device mobility and right ventricular lead dysfunction.
    2 context sentences
    Summary · context
    Chest x-ray revealed lead entanglement consistent with Twiddler syndrome, which is a mechanical complication in which a pacemaker or ICD rotates within its pocket, causing the leads to twist or dislodge and resulting in device malfunction.
    Summary · context
    52-year-old woman with cardiac sarcoidosis and a dual-chamber implantable cardioverter defibrillator (ICD) was treated with semaglutide for refractory obesity (body mass index (BMI) of 40.1 (kg/m2)).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.